OSCR
Oscar Health, Inc.
OSCR has the edge over PRGO overall, supported by stronger fundamentals and stronger modeled upside.
PRGO
Perrigo Company plc
PRGO has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PRGO Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Weak |
PRGO's revenue is currently stable, but its profitability, cash flow and balance sheet are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PRGO PE Valuation
PRGO has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over PRGO on the outlook, with more favorable revenue expectations.
PRGO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PRGO's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PRGO on earnings quality, reporting a profit while its opponent remains loss making.
PRGO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.53 | — |
| Q3 2026 | -$12.77 | -$12.39 |
| Q2 2026 | -$12.52 | -$11.94 |
| Q1 2026 | -$13.11 | -$11.80 |
| Q4 2025 | -$10.29 | -$9.04 |
| Q3 2025 | -$0.38 | +$0.78 |
| Q2 2025 | -$0.58 | +$0.33 |
| Q1 2025 | -$1.31 | -$1.25 |
| Q4 2024 | -$1.25 | -$1.16 |
PRGO lost $12.77 per share over the past year, a bigger loss than the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PRGO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over PRGO on profitability, with a higher operating margin.
PRGO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $988.6M | -5.2% |
| Q2 2026 | $1B | -3.2% |
| Q1 2026 | $969.2M | -7.2% |
| Q4 2025 | $1.1B | -2.5% |
| Q3 2025 | $1B | -4.1% |
| Q2 2025 | $1.1B | -0.9% |
| Q1 2025 | $1B | -3.5% |
| Q4 2024 | $1.1B | -1.6% |
PRGO's revenue has slid since its 2020 peak: $989M last quarter, down 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.3% | -4.6 points |
| Q2 2026 | 2.3% | -2 points |
| Q1 2026 | -38% | -43 points |
| Q4 2025 | -116% | -126 points |
| Q3 2025 | 7% | -0.4 points |
| Q2 2025 | 4.3% | +6.8 points |
| Q1 2025 | 4.5% | +9.6 points |
| Q4 2024 | 10% | +11 points |
PRGO's operating margin was 2.3% last quarter, down 4.6 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PRGO on cash flow, with more consistent year-over-year improvement.
PRGO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $78.7M | +164% |
| Q2 2026 | $68.3M | +20% |
| Q1 2026 | -$127.4M | -$37.4M |
| Q4 2025 | $148.6M | -46% |
| Q3 2025 | $29.8M | +97% |
| Q2 2025 | $56.7M | +$75.6M |
| Q1 2025 | -$90M | -$63.5M |
| Q4 2024 | $274.9M | +51% |
PRGO still generates free cash flow, though less than at its 2021 peak: $168M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PRGO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -200K shares |
| 1 year | +0.4% | +500K shares |
| 3 years | +1.8% | +2.5M shares |
| 5 years | +4.2% | +5.6M shares |
| Available history | +1.8% | +2.4M shares |
PRGO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PRGO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 5.3x | High |
| Q2 2025 | 5.2x | High |
| Q1 2025 | 6.0x | High |
| Q4 2024 | 7.0x | High |
| Q3 2024 | 10.5x | High |
| Q2 2024 | 11.5x | High |
| Q1 2024 | 8.5x | High |
| Q4 2023 | 6.5x | High |
PRGO's net debt is about 5.3 years of its operating earnings (EBITDA), down from 10 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PRGO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.8 | Neutral |
| Stochastic | 84.4 | Overbought |
PRGO's weekly RSI is 62 (neutral) and its Stochastic is 84 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRGO PE vs Healthcare Sector
| Metric | PRGO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
PRGO has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PRGO on trend strength, trading above more of its moving averages.
PRGO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.6 | 3.5% above |
| 20 week MA | $13.7 | 18% above |
| 50 week MA | $12.8 | 26% above |
| 100 week MA | $18.5 | 13% below |
| 200 week MA | $24.9 | 35% below |
PRGO has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 35% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PRGO on returns for 2026, with the stronger performance.
PRGO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.9 | $44.0 | -15% |
| 2021 | $44.0 | $39.5 | -10% |
| 2022 | $39.5 | $33.0 | -16% |
| 2023 | $33.0 | $32.2 | -2.5% |
| 2024 | $32.2 | $25.6 | -20% |
| 2025 | $25.6 | $13.8 | -46% |
| 2026 YTD | $13.8 | $16.2 | +17% |
PRGO has finished every year since 2020 lower, and it's up 17% so far in 2026.